Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection

Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Dousa, Khalid M, Babiker, Ahmed, Van Aartsen, Daniel, Shah, Neel, Bonomo, Robert A, Johnson, John L, Skalweit, Marion J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
ID Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065501/
https://www.ncbi.nlm.nih.gov/pubmed/30090839
http://dx.doi.org/10.1093/ofid/ofy168
_version_ 1783342880783335424
author Dousa, Khalid M
Babiker, Ahmed
Van Aartsen, Daniel
Shah, Neel
Bonomo, Robert A
Johnson, John L
Skalweit, Marion J
author_facet Dousa, Khalid M
Babiker, Ahmed
Van Aartsen, Daniel
Shah, Neel
Bonomo, Robert A
Johnson, John L
Skalweit, Marion J
author_sort Dousa, Khalid M
collection PubMed
description Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.
format Online
Article
Text
id pubmed-6065501
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-60655012018-08-08 Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection Dousa, Khalid M Babiker, Ahmed Van Aartsen, Daniel Shah, Neel Bonomo, Robert A Johnson, John L Skalweit, Marion J Open Forum Infect Dis ID Case Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection. Oxford University Press 2018-07-18 /pmc/articles/PMC6065501/ /pubmed/30090839 http://dx.doi.org/10.1093/ofid/ofy168 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle ID Case
Dousa, Khalid M
Babiker, Ahmed
Van Aartsen, Daniel
Shah, Neel
Bonomo, Robert A
Johnson, John L
Skalweit, Marion J
Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
title Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
title_full Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
title_fullStr Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
title_full_unstemmed Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
title_short Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
title_sort ibrutinib therapy and mycobacterium chelonae skin and soft tissue infection
topic ID Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065501/
https://www.ncbi.nlm.nih.gov/pubmed/30090839
http://dx.doi.org/10.1093/ofid/ofy168
work_keys_str_mv AT dousakhalidm ibrutinibtherapyandmycobacteriumchelonaeskinandsofttissueinfection
AT babikerahmed ibrutinibtherapyandmycobacteriumchelonaeskinandsofttissueinfection
AT vanaartsendaniel ibrutinibtherapyandmycobacteriumchelonaeskinandsofttissueinfection
AT shahneel ibrutinibtherapyandmycobacteriumchelonaeskinandsofttissueinfection
AT bonomoroberta ibrutinibtherapyandmycobacteriumchelonaeskinandsofttissueinfection
AT johnsonjohnl ibrutinibtherapyandmycobacteriumchelonaeskinandsofttissueinfection
AT skalweitmarionj ibrutinibtherapyandmycobacteriumchelonaeskinandsofttissueinfection

Ejemplares similares